Lung Carcinoma

NIH-3T3 cells with the FGFR2 K660E kinase domain mutation demonstrated an increase in colony formation relative to wild-type in an anchorage-independence assay, which was lost with the introduction of… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

It is clear that patients with FGFR2/Plcγ1/Grb2 relative concentrations as: high/high/low have the poorest prognosis whilst those having FGFR2/Plcγ1/Grb2 as: low/low/high drastically enhances the prog… (full text at CIViC)

PMID 26693065 · Timsah et al., 2015 · Open in CIViC

NIH-3T3 cells with the FGFR2 S320C extracellular domain mutation demonstrated an increase in colony formation in an anchorage-independence assay, which was lost with the introduction of AP24534, BGJ39… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In FGFR-dependent NCI-H1581 lung cancer cells, FGFR2 V564G was identified by saturation mutational scanning as a pemigatinib-resistance mutation and was independently validated by cell-viability and p… (full text at CIViC)

PMID 41361008 · Tangermann et al., 2025 · Open in CIViC

NIH-3T3 cells with the FGFR2 W290C extracellular domain mutation demonstrated an increase in colony formation in an anchorage independent growth assay, which was lost with the introduction of AP24534,… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

DNA was extracted from the paraffin-embedded tissues of 86 NSCLC tissues. 72 of the samples were tested for FGFR3 alterations in exons 7, 10, and 15 by sequencing, and two showed point mutations causi… (full text at CIViC)

PMID 36794128 · Lin et al., 2023 · Open in CIViC

FGFR3 G691R mutations were found in ~5.5% of lung adenocarcinoma patients using NGS and mass-spectrometry. The mutation was further found to transform NIH-3T3 cells and form tumors upon xenotransplant… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

NIH-3T3 cells with the FGFR3 R248C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by treatm… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

NIH-3T3 cells with the FGFR3 S249C extracellular domain mutation demonstrated an increase in colony formation compared to wild-type in an anchorage-independence assay, which was counteracted by the tr… (full text at CIViC)

PMID 23786770 · Liao et al., 2013 · Open in CIViC

In this study, 363 lung adenocarcinoma tumors of Indian origin were analyzed using targeted next-generation sequencing and mass spectrometry genotyping, and FGFR3 mutations were identified in 20 tumor… (full text at CIViC)

PMID 27998968 · Chandrani et al., 2017 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

In a xenograft model, FGFR4 overexpressing HCC827 cells exhibited higher resistance to erlotinib. And also, H1975 cells showed resistance to erlotinib. The combination of erlotinib and FGFR1/2/3/4 inh… (full text at CIViC)

PMID 31027687 · Quintanal-Villalonga et al., 2019 · Open in CIViC

Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.

PMID 22541434 · Kumar et al., 2012 · Open in CIViC

The disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype (TT or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identified gender, smo… (full text at CIViC)

PMID 24758907 · Hong et al., 2014 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

In a preclinical study in an immunocompetent mouse model of lung adenocarcinoma, upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3, aka HAVCR2) was observed … (full text at CIViC)

PMID 26883990 · Koyama et al., 2016 · Open in CIViC

Inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner. Cells transformed with mutant HRAS isoforms Q61L, Q61R and G12V demonstrated equal sensitivity to… (full text at CIViC)

PMID 26544513 · Kiessling et al., 2015 · Open in CIViC

Expression of IGF1R in NSCLC cell lines (n=17) was associated with resistance to EGFR inhibitor gefitinib, however, knock-in or knock-out of IGF1R did not affect gefitinib sensitivity. IGF1R expressio… (full text at CIViC)

PMID 23619944 · Peled et al., 2013 · Open in CIViC

Overexpression of JAK1 in 22 lung cancer cell lines was associated with sensitivity to PKC-inhibitor enzastaurin. Silencing of JAK1 (by small molecule JAK 1/2/3 inhibitor) led to resistance. Overexpr… (full text at CIViC)

PMID 22333600 · Shimokawa et al., 2012 · Open in CIViC

Comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti-PD-L1 therapy. Two activating… (full text at CIViC)

PMID 26014096 · Van Allen et al., 2015 · Open in CIViC

Comprehensive genomic profiling on a tumor and germline sample from a patient with refractory lung adenocarcinoma who achieved marked long-term clinical benefit from anti-PD-L1 therapy. Two activating… (full text at CIViC)

PMID 26014096 · Van Allen et al., 2015 · Open in CIViC

The POSEIDON (NCT03164616) open-label, randomized phase 3 trial included 1,013 patients with metastatic non-small-cell lung cancer (NSCLC), of whom 637 had nonsquamous histology and 612 were evaluable… (full text at CIViC)

PMID 39385035 · Skoulidis et al., 2024 · Open in CIViC

A retrospective analysis of 871 non-squamous NSCLC patients treated with chemotherapy (platinum compound plus pemetrexed) combined with immunotherapy (pembrolizumab) found that those with KEAP1 mutati… (full text at CIViC)

PMID 39385035 · Skoulidis et al., 2024 · Open in CIViC

Case report of a 50-year-old male with Stage 1 Lung adenocarcinoma. NGS detected the presence of KIF5B::EGFR fusion (exon 15 and exon 18). The patient received two cycles of chemotherapy but experienc… (full text at CIViC)

PMID 34163176 · Wang et al., 2021 · Open in CIViC

This case study reports the first case of a KIF5B-EGFR fusion (KIF5B exon 15–EGFR exon 18) in primary lung adenocarcinoma. The patient showed a significant partial response to afatinib and bevacizumab… (full text at CIViC)

PMID 32903808 · Xu et al., 2020 · Open in CIViC

A 56 year old woman presents with poorly differentiated stage IIIC lung adenocarcinoma. Chemoradiotherapy and 12-month durvalumab was administered with significant response. 11 months after durvalumab… (full text at CIViC)

PMID 36033470 · Lin et al., 2022 · Open in CIViC

A patient with stage IV NSCLC were treated with CDDP+PEM+Bmab, CBDCA+GEM, pembrolizumab and SAIT301 (met inhibitor). After disease progression, she was received crizotinib and exhibited a dramatic res… (full text at CIViC)

PMID 29102694 · Cho et al., 2018 · Open in CIViC

Case report of a 74-year old woman with EGFR- and ALK-negative lung adenocarcinoma. FISH identified a deletion of 5'RET (FISH, indicating RET-gene rearrangement) and genomic testing confirmed a fusion… (full text at CIViC)

PMID 25982012 · Subbiah et al., 2015 · Open in CIViC

A patient with a KIF5B::RET fusion positive NSCLC with brain metastases who had acquired resistance to alectinib experienced a dramatic response to the selective RET inhibitor selpercatinib (LOXO-292)… (full text at CIViC)

PMID 29912274 · Subbiah et al., 2018 · Open in CIViC

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC)

PMID 31988000 · Solomon et al., 2020 · Open in CIViC

A RET fusion-positive NSCLC patient who had been treated with multiple lines of chemotherapy and targeted therapies received selpercatinib. The patient initially tolerated selpercatinib achieving a sy… (full text at CIViC)

PMID 31988000 · Solomon et al., 2020 · Open in CIViC

We established inducible KIF5B-RET transgenic mice and KIF5B-RET-dependent cell lines for preclinical modeling of KIF5B-RET-associated lung adenocarcinoma. By culturing cells with increasing concentra… (full text at CIViC)

PMID 27496134 · Huang et al., 2016 · Open in CIViC

In a stage IV lung adenocarcinoma patient harboring a KIT D816G mutation, the KIT D816G mutation was associated with crizotinib resistance. The patient was initially found to harbor a ROS1 gene rearra… (full text at CIViC)

PMID 27068398 · Dziadziuszko et al., 2016 · Open in CIViC

Ba/F3 cells harboring the KIT L576P mutation are sensitive to nilotinib, imatinib and lower concentrations of dasatinib.

PMID 17372901 · Antonescu et al., 2007 · Open in CIViC

In a retrospective pan-cancer analysis of four immune checkpoint therapy (ICT)–treated cohorts (melanoma n = 287; NSCLC n = 131; total n = 418), KMT2 family mutations were associated with improved ICT… (full text at CIViC)

PMID 33653367 · Zhang et al., 2021 · Open in CIViC

In preclinical lung squamous cell carcinoma models, KMT2D loss increased sensitivity to SHP2 inhibition (SHP099) and pan-ERBB inhibition (afatinib). Enhanced growth suppression was observed in Kmt2d-d… (full text at CIViC)

PMID 36525973 · Pan et al., 2023 · Open in CIViC

In preclinical lung adenocarcinoma (LUAD) models, loss-of-function KMT2D (truncating/inactivating) was associated with greater sensitivity to glycolysis inhibition, most consistently 2-deoxy-D-glucose… (full text at CIViC)

PMID 32243837 · Alam et al., 2020 · Open in CIViC

Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led… (full text at CIViC)

PMID 24836576 · Van Allen et al., 2014 · Open in CIViC

To characterize crizotinib resistant tumors, three patient cases with established MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC) samples were all found to have gained amplification of… (full text at CIViC)

PMID 30072474 · Bahcall et al., 2018 · Open in CIViC

To determine the origin of drug resistance in MET amplified cell lines, MET small-molecule inhibitors PHA-665752 or JNJ38877605 were tested in cell lines harboring MET amplification. In cell line GR15… (full text at CIViC)

PMID 20841479 · Cepero et al., 2010 · Open in CIViC

KRAS mutations in lung cancer patients are not associated with smoking history, age or gender.

PMID 18794081 · Riely et al., 2008 · Open in CIViC

There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.

PMID 11208838 · Schiller et al., 2001 · Open in CIViC

In a prospective study of 522 European non-small cell lung cancer patients, patients with a KRAS exon 2 mutation (42/307) treated with erlotinib as a second-, third-line or more treatment were associa… (full text at CIViC)

PMID 22982650 · Cadranel et al., 2012 · Open in CIViC

KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) wer… (full text at CIViC)

PMID 19794967 · Marchetti et al., 2009 · Open in CIViC